Robotic navigation system for magnetic ablation catheters cleared
Click Here to Manage Email Alerts
Stereotaxis announced that its system for robotic navigation of magnetic ablation catheters to treat arrhythmias has been cleared by the FDA.
The system (Genesis RMN) has been cleared to navigate an array of compatible interventional devices within all chambers of the heart and coronary vasculature, and also in the neurovascular and peripheral vascular systems, according to a press release from the company.
The new system is 70% to 80% faster than its predecessor, and is smaller, lighter and more flexible than previous systems to provide greater access to the patient and increase available space in labs, according to the release.
“Genesis is a leap forward in robotic magnetic navigation technology,” David Fischel, chairman and CEO of Stereotaxis, said in the release. “We are confident Genesis will have a meaningful impact on patients, physicians and providers in electrophysiology. Genesis is a reflection of our commitment to positively transform interventional medicine with robotics.”
The technology has been used on more than 100,000 patients in more than 100 hospitals around the world, according to the release.
Disclosure: Fischel is an employee of Stereotaxis.